Dong Yao, Gai Zhonghui, Han Mei, Zhao Yunjiao
Department of Research and Development, Wecare Probiotics Co., Ltd., Suzhou, China.
Department of Food Quality and Safety, Shanghai Business School, Shanghai, China.
Front Microbiol. 2024 Oct 8;15:1483104. doi: 10.3389/fmicb.2024.1483104. eCollection 2024.
This study aimed to investigate the effects of low-dose dextran sulfate sodium (DSS) on the induction of chronic mild inflammation in mice and to evaluate the therapeutic potential of LRa05 (LRa05) to ameliorate the associated effects. The focus was on investigating changes in inflammatory, gut microbiota, serum lipopolysaccharide (LPS) and inflammatory cytokines.
Mice were exposed to a low-dose of DSS to induce chronic mild inflammation and LRa05 was administered as a probiotic intervention. The experiment included determination of body weight, colon length, histological examinations, and analysis of LPS and inflammatory cytokines in serum over 12 weeks. In addition, liver function, oxidative stress and intestinal microbiota were examined to understand the comprehensive effects of DSS and LRa05.
Low-dose DSS did not lead to significant changes in body weight, colon length or histologic signs of inflammation. However, it led to a significant increase in serum levels of LPS, tumor necrosis factor-alpha (TNFα) and interleukin-6 (IL6). Intervention with LRa05 effectively attenuated these changes, particularly by lowering LPS levels and normalizing inflammatory cytokines. In addition, LRa05 protected against DSS-induced liver function damage and attenuated oxidative stress in the liver. Analysis of the gut microbiota demonstrated dynamic regulatory effects, where LRa05 intervention led to significant shifts in microbial populations, promoting a balanced microbiota profile. These changes are indicative of dynamic regulation by LRa05 in response to chronic mild inflammation, highlighting the probiotic's role in modulating the gut environment.
The LRa05 intervention showed multi-layered regulation in the chronic mild inflammation model by reducing inflammatory cytokines, maintaining liver function and restoring the balance of the gut microbiota. This provides experimental support for the potential use of LRa05 in chronic inflammation-related diseases and emphasizes the importance of probiotics for overall health. The study suggests that LRa05 is a potential therapeutic agent for the treatment of chronic inflammation associated with gut dysbiosis.
本研究旨在探讨低剂量硫酸葡聚糖钠（DSS）对诱导小鼠慢性轻度炎症的影响，并评估LRa05改善相关影响的治疗潜力。重点是研究炎症、肠道微生物群、血清脂多糖（LPS）和炎症细胞因子的变化。
将小鼠暴露于低剂量DSS以诱导慢性轻度炎症，并给予LRa05作为益生菌干预。实验包括在12周内测定体重、结肠长度、组织学检查以及血清中LPS和炎症细胞因子的分析。此外，还检测了肝功能、氧化应激和肠道微生物群，以了解DSS和LRa05的综合作用。
低剂量DSS未导致体重、结肠长度或炎症组织学体征出现显著变化。然而，它导致血清中LPS、肿瘤坏死因子-α（TNFα）和白细胞介素-6（IL6）水平显著升高。LRa05干预有效地减轻了这些变化，特别是通过降低LPS水平和使炎症细胞因子恢复正常。此外，LRa05可预防DSS诱导的肝功能损害并减轻肝脏中的氧化应激。肠道微生物群分析显示出动态调节作用，其中LRa05干预导致微生物种群发生显著变化，促进了微生物群谱的平衡。这些变化表明LRa05对慢性轻度炎症有动态调节作用，突出了益生菌在调节肠道环境中的作用。
LRa05干预在慢性轻度炎症模型中显示出多层次调节作用，可减少炎症细胞因子、维持肝功能并恢复肠道微生物群的平衡。这为LRa05在慢性炎症相关疾病中的潜在应用提供了实验支持，并强调了益生菌对整体健康的重要性。该研究表明，LRa05是治疗与肠道菌群失调相关的慢性炎症的潜在治疗剂。
